SAP SE

  • WKN: 716460
  • ISIN: DE0007164600
  • Land: Deutschland

Nachricht vom 19.12.2011 | 17:58

SAP AG: Release according to Article 30e of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution


SAP AG  / Third country release according to Article 30e Para. 1, No. 3
of the WpHG [the German Securities Trading Act]

19.12.2011 17:58

Dissemination of a Post-admission Duties announcement according to Article
30e Para. 1 No. 3 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

With ad hoc announcement dated December 3, 2011 SAP AG ('SAP') announced that SAP's subsidiary, SAP America, Inc., has entered into a definitive merger agreement with SuccessFactors, Inc. ('SuccessFactors') pursuant to which a subsidiary of SAP would offer to acquire all outstanding shares of common stock of SuccessFactors. In connection with this merger agreement, SAP has filed on December 16, 2011 with the U.S. Securities and Exchange Commission (SEC) a Schedule TO-T containing the offer to purchase, letter of transmittal and other documentation pertaining to its offer to purchase all outstanding shares of common stock of SuccessFactors. The documentation filed on December 16, 2011 comprises the following: A Schedule TO-T including - 'Exhibit (a)(1)(A) - Offer to Purchase dated December 16, 2011' - 'Exhibit (a)(1)(B) - Form of Letter of Transmittal' - 'Exhibit (a)(1)(C) - Notice of Guaranteed Delivery' - 'Exhibit (a)(1)(D) - Form of Letter to Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees' - 'Exhibit (a)(1)(E) - Form of Letter to Clients for Use by Brokers, Dealers, Commercial Banks, Trust Companies and Other Nominees' - 'Exhibit (a)(1)(F) - Guidelines for Certification of Taxpayer Identification Number on Substitute Form W-9' - 'Exhibit (a)(5)(A) - Press release issued by SAP AG and SuccessFactors on December 3, 2011 incorporated herein by reference to the Form 6-K furnished by SAP AG, SAP America and the Purchaser on December 5, 2011' - 'Exhibit (a)(5)(B) - Summary Advertisement as published in the Wall Street Journal on December 16, 2011' - 'Exhibit (a)(5)(C) - Press release issued by SAP AG on December 16, 2011' - 'Exhibit (b)(1) - Euro 1 billion Credit Facility Agreement dated December 3, 2011, among SAP AG, as borrower, J.P. Morgan Limited as mandated lead arranger, the financial institution listed in Schedule 1 as original lender, and J.P. Morgan Europe Limited, as agent' - 'Exhibit (d)(1) - Agreement and Plan of Merger dated as of December 3, 2011 by and among SAP America, the Purchaser and SuccessFactors incorporated by reference to Exhibit 2.1 to the Current Report on Form 8-K filed by SuccessFactors on December 5, 2011' - 'Exhibit (d)(2) - Mutual Non-Disclosure Agreement effective as of October 20, 2011 between SAP AG and SuccessFactors' - 'Exhibit (d)(3) - Exclusivity Agreement dated as of November 9, 2011 between SAP AG and SuccessFactors' - 'Exhibit (d)(4) - Amended and Restated Exclusivity Agreement dated as of November 22, 2011 between SAP AG and SuccessFactors' - 'Exhibit 99.2 - Power of Attorney' These documents are available on the website of SAP AG under http://www.sap.com/corporate-en/investors/successfactors/offer.epx. 19.12.2011 DGAP's Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de
Language: English Company: SAP AG Dietmar-Hopp-Allee 16 69190 Walldorf Germany Internet: www.sap.com End of Announcement DGAP News-Service

GBC im Fokus

Neovacs S.A.: Kurzfristige Potenziale durch Fast-Track-Zulassung möglich

Das in Frankreich ansässige Biotechnologieunternehmen Neovacs S.A. fokussiert sich auf die Entwicklung so genannter Kinoide, welche für die Behandlung von Autoimmunerkrankungen sowie entzündlichen Erkrankungen verwendet werden. Der Neovacs-Wirkstoff wird derzeit im Rahmen einer klinischen Studie IIb (SLE) in 19 Ländern (Europa, Asien, Lateinamerika, USA) an 178 Patienten untersucht. Wir rechnen mit den ersten Ergebnissen in Sommer 2017. Im Rahmen des DCF-Bewertungsmodells haben wir inkl. eines hohen Sicherheitsabschlages einen fairen Wert von2,90 € je Aktie ermittelt. Wir vergeben das Rating KAUFEN.

News im Fokus

Commerzbank: Vorläufige Kapitalquote CET 1 per Ende Juni 2016 bei 11,5 % - Operatives Ergebnis und Konzernergebnis im zweiten Quartal 2016 im Rahmen des Konsens

25. Juli 2016, 21:37

Aktueller Webcast

Mobimo Holding AG

Presentation of the interim results 2016

04. August 2016

Aktuelle Research-Studie

Original-Research: Solutions 30 SE (von Sphene Capital GmbH): Buy Solutions 30 SE

26. Juli 2016